Skip to content

Management of Menopausal Syndrome by ayurvedic drug (vayasthapana gana choorna orally)and vayasthapana gana ksheerapaka vasti(treatment procedure)

Role of Vayasthapana Gana Choorna and Vayasthapanagana Ksheerapaka Basti in the Management of Rajonivritijanya Lakshana: A Randomized Comparative Clinical Trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012392
Enrollment
100
Registered
2018-03-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Menopausal Patients

Interventions

Intervention1: 1.Vayasthapana Gana choorna: Guduchi - Tinospora cordifolia Haritaki-Terminalia chebula Amalaki-Emblica officinale Rasna- Pluchea lanceolata Aparajita-Clitora ternetia Jivanti -Leptaden

Sponsors

Prof Laxmipriya Dei
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age group between 45-65 years having symptoms as per Australasian Menopause Society Diagnosing Menopause: Symptom Score Sheet, having score 15 or more.

Exclusion criteria

Exclusion criteria: ï?? Age below 45years and age more than 65 years. ï?? Diagnosed cases of disorders of reproductive tract like TB ,Carcinoma ï?? Patients with Hypertension (average systolic bloodpressure greater than or equal to 180 mm Hg or an average diastolic blood pressure greater than or equal to 110 mm Hg).11 ï?? Patients having known history of cardiac disease. ï?? Patients having FBS greater than 250mg/dl ï?? Established case of mental illness. ï?? Patients having hyperthyroidism and hypothyroidism.

Design outcomes

Primary

MeasureTime frame
Changes in the severity of symptoms were assessed by MENQOL (Menopause Specific Quality Of Life) Questionnaire, Menopause Rating Scale.Timepoint: During 2 month treatment and after one month follow up

Secondary

MeasureTime frame
improvement of quality of life in menopausal women. Timepoint: durimg two months treatment and after one month follow up.

Countries

India

Contacts

Public ContactLaxmi Priya Dei

IPGT and RA Jamnagar

deilaxmipriya@yahoo.com7874982753

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026